Syndax Pharmaceuticals Inc
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Shares Outstanding
- 89.3M
- Free Float
- 92.1%
Income Statement
- Revenue
- $172.4M
- Operating Income
- -$273.1M
- Net Income
- -$285.4M
- EBITDA
- -$267.1M
Cash Flow
- Free Cash Flow
- -$323.2M
- FCF Yield
- -19.3%
- Owner FCF Yield
- -22.1%
Balance Sheet
- Cash & Equivalents
- $134.9M
Returns & Capital
- SBC, 3Y Avg
- $40.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $172.4M | -$323.2M | -187.5% |
| FY2024 | $23.7M | -$274.9M | -1160.9% |
| FY2023 | $0 | -$160.6M | — |
| FY2022 | $0 | -$133.7M | — |
| FY2021 | $139.7M | $29.0M | 20.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back